On February 9, 2026, Memo Therapeutics AG announced it has entered into a strategic collaboration and exclusive option-to-license agreement with Carlisle, a global leader in rare disease and serious therapeutic development. The agreement centers on MTx's recombinant polyclonal IgG technology.

Under the terms of the collaboration and option agreement, MTx will utilize its proprietary DROPZYLLA® technology platform to develop recombinant polyclonal IgG products. This platform is designed for cloning human antibody repertoires and expressing polyclonal antibodies. Carlisle secures an exclusive license option for the resulting products. The total potential value of the agreement could reach up to 265 million Swiss francs, equivalent to $328 million.

The DROPZYLLA® platform is an innovative technology based on recombinant polyclonal IgG. It is capable of capturing and replicating natural human antibody libraries on a large scale, enabling the stable and controllable expression of a diverse population of antibodies. These antibodies can be customized to target specific infectious or immune-mediated diseases.

Erik van den Berg, CEO of MTx, stated, "IgG immunotherapy is used to treat a range of conditions, including congenital or acquired immunodeficiencies and autoimmune diseases. Our collaboration with Carlisle further validates our proprietary DROPZYLLA® technology platform and our shared ambition to advance innovative IgG solutions."

Dr. Michael Wilson, Senior Vice President of Global Research at Carlisle, commented, "This research collaboration combines Carlisle's global leadership and expertise in immunoglobulins and recombinant proteins with Memo Therapeutics' recombinant polyclonal technology. It aims to explore new treatment possibilities for patients with rare and serious conditions."